We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Puma (PBYI) Neratinib's NDA Accepted for Review, Stock Up
Read MoreHide Full Article
Puma Biotechnology, Inc.’s (PBYI - Free Report) shares gained 10.5% after the company announced that its New Drug Application (NDA) for its lead candidate, neratinib (PB272), has been accepted for review by the FDA.
The company is looking to get neratinib approved as an extended adjuvant treatment of patients with early-stage HER2-overexpressed/amplified breast cancer, who have been previously treated with Roche Holding AG’s (RHHBY - Free Report) Herceptin (trastuzumab)-based adjuvant therapy.
In Jul 2016, Puma Biotech submitted the regulatory application based on results from a phase III (ExteNET) study, which demonstrated a statistically significant reduction (33%) in the risk of invasive disease recurrence or death, in comparison to placebo.
We remind investors that last month, the company’s Marketing Authorisation Application (MAA) for neratinib was validated by the European Medicines Agency (EMA).
Currently, neratinib is in several breast cancer studies. Data from these studies are expected in the second half of 2016 and beyond. Although the company is exploring the possibility of developing an intravenous formulation of neratinib, it is currently focused on an oral formulation of the candidate.
Puma Biotech believes that neratinib can also be developed for the treatment of other types of cancers, including non-small cell lung cancer (NSCLC) and other tumor types that over-express or have a mutation in HER2.
We note that the breast cancer market is heavily crowded with drugs like Faslodex, Ibrance, Herceptin and Femara among others.
With no approved product in the company’s portfolio and neratinib being its lead pipeline candidate, we expect investor focus to remain on updates pertaining to its development. A potential approval will enable the company to generate product revenues for the first time.
Puma Biotech currently carries a Zacks Rank #2 (Buy). A couple of other favorably placed stocks in the health care sector are Anika Therapeutics, Inc. (ANIK - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Puma (PBYI) Neratinib's NDA Accepted for Review, Stock Up
Puma Biotechnology, Inc.’s (PBYI - Free Report) shares gained 10.5% after the company announced that its New Drug Application (NDA) for its lead candidate, neratinib (PB272), has been accepted for review by the FDA.
The company is looking to get neratinib approved as an extended adjuvant treatment of patients with early-stage HER2-overexpressed/amplified breast cancer, who have been previously treated with Roche Holding AG’s (RHHBY - Free Report) Herceptin (trastuzumab)-based adjuvant therapy.
In Jul 2016, Puma Biotech submitted the regulatory application based on results from a phase III (ExteNET) study, which demonstrated a statistically significant reduction (33%) in the risk of invasive disease recurrence or death, in comparison to placebo.
We remind investors that last month, the company’s Marketing Authorisation Application (MAA) for neratinib was validated by the European Medicines Agency (EMA).
PUMA BIOTECHNLG Price
PUMA BIOTECHNLG Price | PUMA BIOTECHNLG Quote
Currently, neratinib is in several breast cancer studies. Data from these studies are expected in the second half of 2016 and beyond. Although the company is exploring the possibility of developing an intravenous formulation of neratinib, it is currently focused on an oral formulation of the candidate.
Puma Biotech believes that neratinib can also be developed for the treatment of other types of cancers, including non-small cell lung cancer (NSCLC) and other tumor types that over-express or have a mutation in HER2.
We note that the breast cancer market is heavily crowded with drugs like Faslodex, Ibrance, Herceptin and Femara among others.
With no approved product in the company’s portfolio and neratinib being its lead pipeline candidate, we expect investor focus to remain on updates pertaining to its development. A potential approval will enable the company to generate product revenues for the first time.
Puma Biotech currently carries a Zacks Rank #2 (Buy). A couple of other favorably placed stocks in the health care sector are Anika Therapeutics, Inc. (ANIK - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . Both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>